Ahead of its business plan, Andera Partners approaches 4 billion euros in assets under management and announces a new 2028 target of 6 to 8 billion euros
Newron reports striking one-year interim efficacy results from its Phase II clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia
Spexis and SPRIM Global Investments (SGI) announce plans for clinical trial partnership to fund up to half of the projected Phase 3 clinical development costs of ColiFin®